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Abstract
Early diagnosis of sepsis, rapid identiﬁcation of the causative pathogen(s) and prompt initiation of appropriate antibiotic treatment have a
combined impact on mortality due to sepsis. In this observational study, a new DNA-based system (LightCycler SeptiFast (LC-SF) test;
Roche Diagnostics) allowing detection of 16 pathogens at the species level and four groups of pathogens at the genus level has been eval-
uated and compared with conventional blood cultures (BCs). One hundred BC and LC-SF results were obtained for 72 patients admitted
to the intensive-care unit over a 6-month period for suspected sepsis. Microbiological data were compared with other biological parame-
ters and with clinical data. The positivity rate of BCs for bacteraemia/fungaemia was 10%, whereas the LC-SF test allowed detection of
DNA in 15% of cases. The LC-SF performance, based on its clinical relevance, was as follows: sensitivity, 78%; speciﬁcity, 99%; positive
predictive value, 93%; and negative predictive value, 95%. Management was changed for four of eight (50%) of the patients because organ-
isms were detected by the LC-SF test but not by BC. LC-SF results were obtained in 7–15 h, in contrast to the 24–72 h required for
BC. According to the LC-SF results, initial therapy was inadequate in eight patients, and antibiotic treatment was changed. Our results
suggest that the LC-SF test may be a valuable complementary tool in the management of patients with clinically suspected sepsis.
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Introduction
Rapid detection of bacteraemia and fungaemia is one of the
most important functions of the bacteriology laboratory.
Microbiological documentation is of paramount importance
for the success of the therapeutic strategy during sepsis, as
well as for the adequacy of the treatment (delay of <24–
48 h) [1]. Microbial documentation has a great impact
on mortality and morbidity [2,3]. For instance, rapid and
substantiated management of sepsis is recommended for
infections due to Pseudomonas aeruginosa [4] and Staphylococ-
cus aureus [5].
Results from traditional blood culture (BC) (and other
specimens) are usually not available until 24–72 h after initial
patient presentation or suspected new episodes of infection,
necessitating initial use of empirical therapy. During the ﬁrst
24 h of suspected sepsis, initial antibiotic therapy is reported
to be inappropriate in 10–60% of cases (i.e. one or more
detected pathogens not covered by, or resistant to, the cho-
sen antibiotics) [2,6]. Inappropriate antibiotic therapy is asso-
ciated with mortality ranging from 10–45% [1], with
emerging antibiotic resistance [2] in intensive-care units
(ICUs), and with longer hospital length of stay [6,7].
Targeting antibiotic therapy to causative pathogens is
pivotal in reducing resistance; however, greater accuracy of
appropriate antibiotic selection requires more rapid and
sensitive diagnostic tools for the identiﬁcation of potential
pathogens. The advent of non-culture-based identiﬁcation of
blood-borne pathogens by the detection and identiﬁcation of
bacterial and fungal DNA directly in the blood of patients
with suspected early sepsis has the potential to allow
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targeted antibiotic therapy. This may lead to drug cost
savings, shorter duration of therapy, shorter hospital length
of stay, and reduction in overall resistance rates.
A few years ago, a method consisting of a DNA probe
matrix directed towards rRNA gene targets utilizing seven
probe cocktails was proposed [8]. Only positive BC samples
were subjected to this technique, giving results within 1 h
with very good sensitivity (100%) and speciﬁcity (96%). More
recently, some studies have reported the use of real-time
PCR to detect bacteria either from BC [9] or directly from
patient blood [10–13].
The LightCycler SeptiFast (LC-SF) test (Roche Diagnostics
GmbH, Mannheim, Germany) was developed to detect
directly from blood the 20 most important bacterial and fun-
gal genera or species (Table 1), causing 90% of all blood-
stream infections in patients admitted to ICUs [2,7,14]. The
present article reports a prospective observational study
performed in patients admitted to the ICU with suspected
bloodstream infection, using this multiplex real-time PCR kit
in comparison with conventional BC in the daily routine.
Materials and Methods
Study patients and setting
This prospective observational cohort study was performed
in a 30-bed ICU during a 6-month period. Because it was
observational, Institutional Review Board approval was not
required according to French law. All adult patients with
fever (‡38C) or hypothermia (£36C) were eligible. Clinical
data were prospectively collected at ICU admission and
throughout the hospitalization period. The patient status was
deﬁned according to SIRS criteria [15,16]. Antimicrobial pre-
scription was prospectively recorded on the day of BC sam-
pling. Other microbiological specimens were collected for
testing as clinically indicated.
BC
A single venipuncture was used to collect blood (10 mL for
each BC). BC consisted of the following: (i) a pair of bottles
(aerobic and anaerobic) incubated for 5 days at 37C and
analysed for bacteria using BacT/Alert (bioMe´rieux, Marcy
l’Etoile, France); and (ii) one bottle with Mycosis medium
incubated for 14 days at 37C and analysed for fungi with
BACTEC 9200 (BD, Pont-de-Claix, France). From the same
venipuncture, 5 mL of EDTA whole blood was collected for
the LC-SF test. Microorganisms isolated from BC were iden-
tiﬁed according to standard laboratory methods and good
laboratory practice.
The LC-SF test
The LC-SF test is based on three major processes: (i) specimen
preparation with mechanical lysis and puriﬁcation of DNA;
(ii) real-time PCR ampliﬁcation of target DNA in three paral-
lel reactions (Gram-positive bacteria, Gram-negative bacteria,
and fungi) and detection with speciﬁc hybridization probes;
and (iii) automated identiﬁcation of species and controls
[17]. Target species detected using the LC-SF test are shown
in Table 1.
The LC-SF test uses proprietary broad-range PCR primers
to amplify unique portions of the bacterial or fungal internal
transcribed sequences for a particular bacterial or fungal spe-
cies. A deﬁned volume containing an internal control (IC) is
introduced into each specimen along with the lysis solution.
The IC contains unique probe-binding regions that allow dif-
ferentiation of the ampliﬁed IC from the target. The volume
of whole blood for DNA preparation was 1.5 mL. The speci-
mens were prepared and tested as recommended by the
manufacturer [17]. Real-time detection of PCR products was
performed using the LightCycler 2.0 instrument. Melting
temperatures of specimens and controls were analysed using
the LC-SF identiﬁcation software, and a report was gener-
ated. Patient data were valid if the corresponding controls
(kit reagent controls and ICs) were positive.
The LC-SF test was performed with fresh blood samples
that were processed individually or in batches of two or
three samples. Instruments and disposables were provided
by Roche Molecular Diagnostics (Roche Diagnostics, Meylan,
France). All disposables and reagents used within the work-
ﬂow were labelled MGRADE (DNA-free) and IVD/CE.
TABLE 1. Target species of the
LightCycler SeptiFast test
Gram-negative Gram-positive Fungi
Escherichia coli Staphylococcus aureus Candida albicans
Klebsiella (pneumoniae/oxytoca) Coagulase-negative staphylococci (Staphylococcus
epidermidis, Staphylococcus haemolyticus)
Candida tropicalis
Candida parapsilosis
Serratia marcescens Streptococcus pneumoniae Candida krusei
Proteus mirabilis Streptococcus spp. (Streptococcus pyogenes,
Streptococcus agalactiae, Streptococcus mitis)
Candida glabrata
Enterobacter (cloacae/aerogenes) Aspergillus fumigatus
Enterococcus faecium
Pseudomonas aeruginosa Enterococcus faecalis
Acinetobacter baumannii
Stenotrophomonas maltophilia
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Statistical methods
SPSS software (SPSS for Windows, version 14.1; SPSS, Chi-
cago, IL, USA) was used for data analysis. The Mann–Whitney
U-test was used to compare demographic data between
subjects with positive BC results and subjects with negative
BC results. Results of the LC-SF test and BC are presented
as positivity rates and by isolate.
Results
From the 72 patients, a total of 100 sample sets of consecu-
tive BC sets (aerobic, anaerobic and fungi) and LC-SF sam-
ples were examined. A total of 14 patients had two sets of
blood samples taken, and seven patients had three sets of
blood samples taken. No statistically signiﬁcant differences in
demographic data or cause for ICU admission were found
between patients with negative BC results and those with
positive BC results (p >0.05). The most frequent suspected
site of infection was the respiratory tract: 66% (59/90) of
samples with negative BC results, and 70% (7/10) of samples
with positive BC results. The time from blood draw to deliv-
ery of the LC-SF results to the clinician ranged from 7 to
15 h.
Table 2 shows the 102 results from the 100 paired sam-
ples. In six patients, BCs were positive alone: Escherichia coli
was previously isolated from a bursitis; Leuconostoc spp., not
included in the panel, were considered by physicians as
translocated intestinal bacteria; Staphylococcus epidermidis was
considered to be a contaminant from blood drawing. No
explanation was found for the recovery of Enterobacter (cloa-
cae/aerogenes).
The results of positive cases as determined with the
LC-SF test are reported in Table 3. Two yeasts were
detected only in BCs but not by the LC-SF test: Candida glab-
rata/S. aureus (patient 4) and Candida albicans/Candida tropical-
is (patient 9). In the ﬁrst case, C. glabrata was recovered
from the throat and urine 5 days before the LC-SF test. For
the second case, C. albicans was previously isolated from
bronchial secretions 15 days before the LC-SF test.
In comparing LC-SF results with those from BC, the
parameters of analytical performance of the test were as fol-
lows: sensitivity, speciﬁcity, positive predictive value (PPV)
and negative predictive value (NPV) were 40%, 88%, 27%,
and 93%, respectively.
In eight patients, organisms were detected by the LC-SF
test but BC results were negative (Table 3). On the basis of
LC-SF results and microbiological data, antibiotic manage-
ment was changed in three patients (patients 2, 3 and 6). In
two of these patients (patients 3 and 6), initial therapy was
considered to be inadequate. Patient 2, without antibiotics,
received antibiotics on day 6 because of the positivity of the
LC-SF result (E. coli). In patient 5, although the antibiotic
management was considered to be adequate, a catheter was
withdrawn following the LC-SF test because the physician
considered the catheter to be the focus of infection. Four
patients (patients 1, 4, 7 and 8) with positive LC-SF results
were already receiving appropriate treatment at the time of
the LC-SF test, and no change was made to their antibiotic
regimen. Table 3 shows that initial therapy was inadequate in
four patients, and management was changed as shown for
these patients.
From the 11 discrepant cases (Table 3; nine LC-SF-positive/
BC-negative, and two LC-SF-positive/BC-discrepant), ten were
TABLE 2. Test results for all paired
blood samplesa
LightCycler
SeptiFast test result
Blood culture result
Positive Negative
Positive Serratia marcescens n = 3 Escherichia coli n = 2
Staphylococcus aureus n = 1 Klebsiella pneumoniae n = 3
S. aureus n = 4b
Pseudomonas aeruginosa n = 1
Candida tropicalis n = 1c
Total = 4 Total = 11
Negative Escherichia coli n = 1 n = 81
Enterobacter cloacae n = 1
Leuconostoc spp. n = 1d
Staphylococcus epidermidis n = 1d
Candida glabrata n = 1b
Candida albicans n = 1c
Total = 6 Total = 81
aOne hundred and two microorganisms detected from 100 paired blood cultures and the LightCycler SeptiFast test.
bOrganisms were detected from the same blood sample (applies to only one of the four blood culture-negative
S. aureus results).
cOrganisms were detected from the same blood sample.
dOrganisms isolated only by blood culture and not considered to be clinically relevant by the clinician: one case of
contamination (S. epidermidis) and one case of possible intestinal translocation (Leuconostoc spp.).
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considered to be true-positive results, given the clinical ﬁnd-
ings and other microbiological results. In addition, two sam-
ples with negative LC-SF results but positive BC results were
ultimately considered to be not clinically meaningful (Table 2).
Thus, the LC-SF performance was adjusted as follows: sensitiv-
ity, 78%; speciﬁcity, 99%; PPV, 93%; and NPV, 95%.
Discussion
The LC-SF test is the ﬁrst DNA-based test to detect micro-
organisms directly from blood without the need for prior
incubation. Such a test has great potential to optimize the
management of patients with suspected sepsis. In the present
study, the rate of recovery from bacteraemia was apparently
better with the LC-SF test than with conventional BC. How-
ever, these results raise three questions: (i) what is the clini-
cal relevance of isolates detected only with the LC-SF test;
(ii) does the DNAemia found by PCR reﬂect true infection;
and (iii) what is the best design for such a comparison
between BC and DNA-based tests? There are no data in the
literature on the presence of circulating bacterial DNA in
blood, even from patients with subclinical bacterial infections.
In contrast, it is well known that the release and circulation
of fungal DNA is variable or present in the blood at a very
low concentration [18,19]. Sometimes, fungal DNA is
detected just within the lower limit of conventional PCR
assays [20]. Moreover, the present study had some design
limitations, mainly concerning the number of sets of BCs.
Indeed, the sensitivity of BCs is increased by culturing
greater volumes of blood, whereas the LC-SF test has been
compared to a set of only three BCs, collected at the same
time. However, the aim of such a molecular test is to reduce
the number of samples while trying to achieve the best pos-
sible sensitivity.
Another aspect is the ampliﬁcation of circulating DNA of
non-viable bacteria and fungi, e.g. that within phagocytic cells
or from bacteria inhibited by antimicrobials. PCR-based
methods are more sensitive than BC. Indeed, in the 11 cases
where bacteria were only detected with the LC-SF test, the
results might be considered to be false positive. However,
the association of clinical ﬁndings and other biological data in
these cases suggested that the bacteria recovered were truly
responsible for the patients’ status. Therefore, in the future,
BC should no longer be the reference standard for the diag-
nosis of bloodstream infections. Among the publications on
this topic, a recent study underlined that false-positive blood
bottles were detected with automated systems, and sug-
gested evaluation of the microbial DNA in these bottles
[21].
It has been well established that the time to appropriate
antibiotic therapy has a signiﬁcant impact on mortality [22].
Similarly, it is also well documented that the rate of inappro-
priate antibiotic use varies and is a strong determinant of
outcome [7]. The LC-SF test provides clinicians with the
opportunity to ﬁne-tune therapeutic management much
earlier than has been previously possible. As this study was
preliminary, the number of patients with positive BC and/or
LC-SF results was small. However, in a number of cases,
patient management was changed in response to the LC-SF
results and in accordance with other available clinical infor-
mation. In particular, a number of these patients had negative
BC results at the time and were already receiving antibiotics.
Patient management was changed in four of eight patients
with positive LC-SF results and negative BC results, although
these patients were already receiving antibiotics. In addition,
for patients with both BC and LC-SF results positive for the
same microorganism, the LC-SF results were available ear-
lier, and patient management could be changed before the
BC results were available. The clinical relevance of the LC-SF
test was determined by the clinicians, as was also the case
for the BC results.
With the LC-SF test, inhibition of PCR was observed
when leukocytosis was greater than 30 000/mm3 (three
cases). This phenomenon, also reported in another study,
was probably due to competition between the relatively low
level of bacterial DNA and the high level of human genomic
DNA, affecting the assay sensitivity [10].
Although the LC-SF test gave a response more quickly
than BC, the current version requires considerable hands-
on technician time in the laboratory, except for the PCR
step. Consequently, it is recommended that assays be per-
formed in batch format. In the laboratory environment, care
had to be taken to avoid contaminants, especially for the
detection of Aspergillus fumigatus in blood. Only Mancini
et al. [13] have detected A. fumigatus in a patient with the
LC-SF test. However, during our study, no exogenous con-
taminant was recovered, owing to close attention to prepa-
ration. Many changes of clothing were made throughout the
study. Laboratory surfaces and appliances were also decon-
taminated frequently. Moreover, PCR ampliﬁcations were
carried out in the presence of uracil-N-glycosylase. Despite
the high degree of precautions and a period of adaptation,
laboratory implementation was easy. Assays were routinely
performed with good practicability. The likelihood of con-
tamination has signiﬁcantly decreased, owing to technical
improvements such as the use of automated real-time PCR
detection.
Our results are slightly better than those obtained by
Louie et al. in terms of speciﬁcity (99% vs. 85%) and sensitiv-
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ity (78% vs. 52%), but Lehmann et al., working with spiked
blood, found the same speciﬁcity as that obtained in the
present study [11,12]. However, in the study by Louie et al.,
cases of contamination were estimated at eight (S. epidermi-
dis), instead of one as in ours.
In conclusion, we are witnessing the development of a
new paradigm in the ﬁeld of infectious diseases. Physicians
receiving a microbiological result within the day of sampling
will be a step ahead in the treatment of infections. At the
International Conference on Biodetection Technologies
(June 2008), this view was supported by Ritter, who pre-
sented the next generation of automated multi-target detec-
tion platforms, which are capable of performing 120
discrete analyses simultaneously. The LC-SF test is the ﬁrst
labelled IVD-CE test for the detection of microorganisms
that is focused on blood from patients admitted to ICUs,
but other methods are currently under development to
achieve the same goal [23,24]. The clinical signiﬁcance of a
result from a PCR-based test such as the LC-SF test must
be interpreted with consideration of all of the available clin-
ical and other laboratory data, and not alone. The results
from this preliminary study suggest that the LC-SF test
might be a valuable complementary tool in the optimal
management of patients with clinically suspected sepsis. A
larger, multicentre, randomized controlled study is in pro-
gress to further evaluate the clinical beneﬁt and consequent
health economic beneﬁts of using the LC-SF test in addition
to traditional culture-based methods of diagnosis of causal
pathogens in patients with sepsis.
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